secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elanco Animal Health Inc (ELAN)
CIK:        0001739104
Form:       8-K
Filed at:   2025-12-09T23:59:59+00:00
Accession:  0001104659-25-119486
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elanco announces restructuring plan and three-year financial outlook; Befrena technical sections complete
--------------------------------------------------------------------------------

- Restructuring: ~300 jobs eliminated, ~300 shifted; ~$175M pretax charge (~$130M cash); closure of Kansas City implant facility, partial exit from Monheim Germany.
- Three-year outlook: mid-single digit revenue growth, high-single digit adj. EBITDA growth, low double-digit adj. EPS growth starting 2026.
- Befrena (IL-31 mAb) technical sections complete; administrative review underway; launch expected H1 2026.
- Innovation revenue ~$1.1B in 2026; 5-6 blockbuster potential approvals expected 2026-2031.
- Elanco Ascend: $200-250M adjusted EBITDA savings by 2030; ~$25M in 2026, ~$60M in 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739104/000110465925119486/0001104659-25-119486-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739104/000110465925119486/tm2533048d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-119486

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer